• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Orange Biomed unveils at-home A1c test in the U.S.

April 19, 2023 By Sean Whooley

Orange Biomed OBM rapid A1c
The OBM rapid A1c system. [Image courtesy of Orange Biomed]
Orange Biomed announced today that it commenced a U.S. launch as it looks to fill testing gaps for pre-diabetes and diabetes.

Seoul, South Korea–based Orange Biomed operates out of Research Triangle Park, North Carolina in the U.S. The company currently has ongoing studies for its OBM rapid A1c test. It designed the glycated hemoglobin analyzer to function through single-cell analysis of red blood cells.

Co-founder Yeaseul Park describes OBM rapid A1c as a portable, guided, five-minute test. It requires only a single drop of blood to produce accurate results. The system integrates lab-level technology into portable devices, making healthcare accessible, accurate and affordable.

Orange Biomed featured in Drug Delivery Business News’ 11 diabetes startups you need to know. The company plans to unveil its latest technology at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in June.

“Current technologies are likely to produce inaccurate A1c results disproportionately more for non-white patients due to hemoglobin variants,” said Park. “Hemoglobin variants are more common in patients with African, South and Southeast Asian, and Mediterranean ancestry. Inaccurate results can delay diabetes diagnosis and serious long-term health damage. We invented a new method of A1c testing, free from hemoglobin variant interference, to facilitate earlier detection and management of diabetes across all patient populations.”

In pre-Series A funding rounds, Orange Biomed brought in more than $2 million in investments. It currently has OBM rapid A1c undergoing global studies with Asan Medical Center. The company aims to garner FDA clearance within one year.

Filed Under: Business/Financial News, Diabetes, Diagnostics, Featured, Patient Monitoring Tagged With: Orange Biomed

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS